Back to Global NewsPublished: 3 Mar 2026Download AppJoin TelegramWhy Theravance's 30% Plunge Signals a Turning Point for Biotech Investors#Theravance Biopharma#Biotech#CYPRESS trial#Ampreloxetine#Investment#RestructuringDownload AppJoin CommunityShare Article